Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
暂无分享,去创建一个
M. Dimon | A. Daud | P. Leboit | K. Chong | T. McCalmont | G. Green | A. Ebaee | C. Posch | S. Ortiz-Urda | H. Moslehi | L. Feeney | V. Feichtenschlager | Li-Jun Peng | Thomas Phillips | Kim Chong
[1] Gerald C. Chu,et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma , 2012, Nature Medicine.
[2] James S. Duncan,et al. Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models , 2012, Clinical Cancer Research.
[3] S. Woodman,et al. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner , 2012, Clinical Cancer Research.
[4] J. Christensen,et al. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice , 2012, Cancer Chemotherapy and Pharmacology.
[5] Laura M. Heiser,et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. , 2012, Cancer discovery.
[6] C. Berking,et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. , 2012 .
[7] A. Ribas,et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines , 2012, Molecular Cancer.
[8] T. Gilmer,et al. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.
[9] F. Kelleher,et al. Targeting NRAS in Melanoma , 2012, Cancer journal.
[10] V. Guallar,et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. , 2012, Biochemical pharmacology.
[11] B. Kholodenko,et al. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. , 2012, Biochemical Society transactions.
[12] H. Temple,et al. mTORC1 inhibition and ECM–cell adhesion-independent drug resistance via PI3K–AKT and PI3K–RAS–MAPK feedback loops , 2012, Tumor Biology.
[13] P. Mischel,et al. Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.
[14] C. Tzen,et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.
[15] Rodney J Hicks,et al. In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.
[16] Q. Mi,et al. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. , 2011, The Journal of investigative dermatology.
[17] C. Klemke,et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.
[18] Q. She,et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.
[19] G. Merlino,et al. Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation , 2010, Oncogene.
[20] William Pao,et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.
[21] David P. Davis,et al. Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors , 2009, PloS one.
[22] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[23] G. Warren,et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. , 2008, Journal of medicinal chemistry.
[24] T. Hunter,et al. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition , 2007, Oncogene.
[25] Kevin Shannon,et al. Targeting oncogenic Ras. , 2007, Genes & development.
[26] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[27] S. Cook. Faculty Opinions recommendation of Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. , 2007 .
[28] G. Stamp,et al. Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.
[29] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[30] C. Niemeyer,et al. Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders , 2006, Cell cycle.
[31] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[32] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[33] D. Ruiter,et al. Analysis of Mutations in B-RAF, N-RAS, and H-RAS Genes in the Differential Diagnosis of Spitz Nevus and Spitzoid Melanoma , 2005, The American journal of surgical pathology.
[34] J. Castro,et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells , 2005, International journal of cancer.
[35] K. Giehl. Oncogenic Ras in tumour progression and metastasis , 2005, Biological chemistry.
[36] G. Reifenberger,et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.
[37] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[38] L. Kanter,et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Hoeffler,et al. Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.
[41] L. J. Veer,et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.